Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$10.62 USD
-0.11 (-1.03%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $10.60 -0.02 (-0.19%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
ARQT 10.62 -0.11(-1.03%)
Will ARQT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ARQT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARQT
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
ARQT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
United Therapeutics (UTHR) Completes Enrolment in IPF Study
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
Other News for ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Have $5-10? 7 Affordable Stocks That Are About to Breakout.